Atara Allogeneic Product ATA188 Will Confirm Whether EBV Infecting B Cells Could Cause a Difficult to Treat Kind of MS

Atara Biotherapeutics ATA188 for MS
Atara Biotherapeutics (ATRA) announced the presentation of initial efficacy data as well as updated safety results from its ongoing Phase 1 study of the firm’s product ATA188 for the treatment of a progressive . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.